{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:27:11Z","timestamp":1679232431617},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0163945","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T17:35:52Z","timestamp":1476466552000},"page":"e0163945","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C"],"prefix":"10.1371","volume":"11","author":[{"given":"Perica","family":"Davitkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apoorva Krishna","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Compan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina G.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald D.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Gideon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yngve","family":"Falck-Ytter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"ref2","article-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","year":"2014"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"GL Armstrong","year":"2006","journal-title":"Annals of internal medicine"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"MM Denniston","year":"2014","journal-title":"Annals of internal medicine"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.20502","article-title":"Elevated prevalence of hepatitis C infection in users of United States veterans medical centers","volume":"41","author":"JA Dominitz","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1478-3231.2006.01430.x","article-title":"Progression to cirrhosis in hepatitis C patients: an age-dependent process","volume":"27","author":"P Pradat","year":"2007","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"17","key":"ref7","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1073\/pnas.87.17.6547","article-title":"Hepatitis C virus infection is associated with the development of hepatocellular carcinoma","volume":"87","author":"I Saito","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"RR-4","key":"ref8","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"BD Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","article-title":"The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry","volume":"174","author":"J McCombs","year":"2014","journal-title":"JAMA internal medicine"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"JG McHutchison","year":"1998","journal-title":"The New England journal of medicine"},{"issue":"9138","key":"ref11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"T Poynard","year":"1998","journal-title":"Lancet"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"S Zeuzem","year":"2000","journal-title":"The New England journal of medicine"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Y Falck-Ytter","year":"2002","journal-title":"Annals of internal medicine"},{"issue":"1","key":"ref14","first-page":"CD005445","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"J Brok","year":"2010","journal-title":"The Cochrane database of systematic reviews"},{"key":"ref15","unstructured":"Boceprevir prescribing information [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202258lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202258lbl.pdf<\/ext-link>."},{"key":"ref16","unstructured":"Telaprevir prescribing information [Internet]. Silver Spring, MD: U.S. Food and Drug Administration; Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201917lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201917lbl.pdf<\/ext-link>."},{"issue":"25","key":"ref17","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"13","key":"ref18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"C Hezode","year":"2014","journal-title":"Gastroenterology"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4254\/wjh.v6.i9.660","article-title":"Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients","volume":"6","author":"D Bonnet","year":"2014","journal-title":"World journal of hepatology"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"KF Schulz","year":"2010","journal-title":"Annals of internal medicine"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890","volume":"59","author":"C Hezode","year":"2013","journal-title":"Journal of hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"a2390","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"M Zwarenstein","year":"2008","journal-title":"BMJ"},{"issue":"20","key":"ref24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"ref25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"ref26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"ref27","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"ref28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"MS Sulkowski","year":"2015","journal-title":"JAMA"},{"key":"ref30"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"J Chhatwal","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir +\/- ribavirin vs. ombitasvir\/paritaprevir\/ritonavir + dasabuvir +\/- ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"LI Backus","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","article-title":"Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/Ritonavir\/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Healthcare System","author":"GN Ioannou","year":"2016","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0163945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:01:49Z","timestamp":1589000509000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0163945"}},"subtitle":[],"editor":[{"given":"Do Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0163945","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}